Henri Termeer joins Verastem board
This article was originally published in Scrip
Executive Summary
Verastem, a biopharmaceutical company focused on discovering and developing cancer drugs by targeting cancer stem cells, has appointed Henri Termeer to its board of directors. Previously Mr Termeer was chairman, president and CEO of Genzyme for nearly 30 years.